MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1

Figures & data

Table 1. The Association of miR-638 expression with clinical characteristics of OSCC patients.

Characteristics	N (n = 107)	miR-638 low expression (n = 48)	miR-638 high expression (n = 59)	P
Age (years)				.131
≥60	56	29	27
<60	51	19	32
Gender				.414
Males	60	29	31
Females	47	19	28
Smoking				.281
Yes	54	27	27
No	53	21	32
Drinking				.899
Yes	55	25	30
No	52	23	29
Differentiation				.133
High-moderate	62	24	38
Low	45	24	21
Lymph node metastasis				.044
Yes	38	22	16
No	69	26	43
TNM stage				.001
I–II	65	21	44
III–IV	42	27	15

Figure 1. Decreased expression of miR-638 in OSCC tissues (A) and cells (B). **P < .01; *P < .05.

Figure 2. The transfection with miR-638 mimic could enhance the expression of miR-638, while transfection with miR-638 inhibitor down-regulated miR-638 (A). Enforced miR-638 could significantly suppress OSCC cells’ proliferation (B), migration (C) and invasion (D), and the knockdown of miR-638 promoted malignant behaviors of OSCC cells. **P < .01; *P < .05.

Figure 3. Bioinformatics analysis demonstrated that the 3′UTR of PLD1 gene had complementary sequences of miR-638 (A). In cells transfected by PLD1-wt, the presence of miR-638 mimic could significantly reduce luciferase activity of the cells, while the co-transfection with miR-638 and PLD1-mt had no obvious influences on luciferase activity of the cells (B). **P < .01.

Figure 4. The expression of PLD1 was significantly up-regulated in SCC-9 cells, compared to non-cancerous HPK cell line (A). Moreover, enforced expression of miR-638 could obviously suppress the expression of PLD1, while miR-638 inhibition up-regulated PLD1 in OSCC (B). ***P < .001; **P < .01.

Figure 5. Western blot images for the expressions of wnt/β-catenin pathway-related proteins in transfected cells (A). Quantitative analysis for western blot results (B). **P < .01; *P < .05.

Figure 6. Western blot analysis for proteins in wnt/β-catenin pathway after the co-transfection with miR-638 inhibitor and si-PLD1 (A). Quantitative analysis for western blot results (B). **P < .01; *P < .05.

Figure 7. Compared to cells transfected by miR-638 inhibitor (control), the co-transfection with miR-638 inhibitor and si-PLD1 significantly suppressed cell proliferation (A), migration (B) and invasion (C). **P < .01; *P < .05.